In malignant tumors, TGF-β is produced by the tumor microenvironment, particularly by CAFs, leading to the activation of EMT in neighboring carcinoma cells, inactivation of TH1 cell differentiation, and immune surveillance escape [110]. The gene discussed is TGFB1; the disease is carcinoma.